Lyra Therapeutics Delivers Clinically Relevant SNOT-22 Score in Sinusitis Treatment Study
Lyra Therapeutics (Nasdaq: LYRA) has announced positive topline results from its BEACON Phase 2 clinical study of LYR-220 in adult patients with chronic rhinosinusitis (CRS) who have had prior ethmoid sinus surgery. The study demonstrated statistically significant and clinically relevant improvements in 3 cardinal symptoms and Sino-Nasal Outcome Test (SNOT-22) scores at 24 weeks.
Brent A. Senior, MD, Coordinating Investigator for the BEACON study, said, “The BEACON study results are very promising, demonstrating significant, long-lasting improvements in patient outcomes with a simple, in-office procedure. If confirmed in Phase 3, these results suggest that Lyra’s technology has the potential to offer ENT physicians a new treatment option to improve symptoms and quality of life for CRS patients.”
LYR-220 is a bioresorbable nasal matrix that is designed to deliver six months of continuous anti-inflammatory medication (7500µg MF) to the sinonasal passages for the treatment of CRS.
The Phase 2 BEACON study is a sham-controlled, parallel-group study to evaluate safety and efficacy of the LYR-220 (7500µg MF) matrix, over a 24-week period, in symptomatic adult CRS patients who have had a prior bilateral ethmoid sinus surgery.
The study demonstrated statistically significant improvement in a composite of the 3 cardinal symptoms of CRS (nasal obstruction, nasal discharge, facial pain/pressure) as early as week 4.
Statistically significant improvements in SNOT-22 were observed as early as week 2 and maintained throughout the study.
The study met its primary safety endpoint, with no serious adverse events observed.
Topline results from the study will be presented at the American Rhinologic Society 69th Annual Meeting on September 30, 2023, in Nashville, TN.
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). Lyra has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal matrices designed to be administered in a simple, in-office procedure and are intended to deliver six months of continuous mometasone furoate (MF) drug therapy (7500µg MF) to the sinonasal passages. LYR-210 is designed for surgically naïve patients and is being evaluated in the ENLIGHTEN Phase 3 clinical program, while LYR-220, an enlarged matrix, is being evaluated in the BEACON Phase 2 clinical study in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery. These two product candidates are designed to treat the estimated four million CRS patients in the United States who fail medical management each year.